Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Oliver Ottmann, Giuseppe Saglio, Jane F. Apperley, Christopher Arthur, Eduardo Bullorsky, Aude Charbonnier, John F. Dipersio, Hagop Kantarjian, Hanna Jean Khoury, Dong Wook Kim, Diane Healey, Lewis Strauss, Jorge E. Cortes

Research output: Contribution to journalLetter

2 Scopus citations
Original languageEnglish (US)
Article number88
JournalBlood Cancer Journal
Volume8
Issue number9
DOIs
StatePublished - Sep 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Ottmann, O., Saglio, G., Apperley, J. F., Arthur, C., Bullorsky, E., Charbonnier, A., Dipersio, J. F., Kantarjian, H., Khoury, H. J., Kim, D. W., Healey, D., Strauss, L., & Cortes, J. E. (2018). Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal, 8(9), [88]. https://doi.org/10.1038/s41408-018-0122-3